Polynovo

Polynovo Equity

The The Equity of Polynovo (PNV.AX) as of Nov 3, 2026 is 90.70 M AUD. In the previous year, The Equity was 83.26 M AUD — a change of 8.93% (higher).

Equity

90.70 MAUD

YoY

8.93%

Last updated:

In 2026, Polynovo's equity was 90.70 M AUD, a 8.93% increase from the 83.26 M AUD equity in the previous year.

The Polynovo Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
26.10 M AUD
Jan 1, 2020
23.81 M AUD
Jan 1, 2021
22.35 M AUD
Jan 1, 2022
17.72 M AUD
Jan 1, 2023
65.38 M AUD
Jan 1, 2024
72.12 M AUD
Jan 1, 2025
83.26 M AUD
Jan 1, 2026
90.70 M AUD
The Polynovo Equity history
YEAREquityYoY
90.70 MAUD+8.93%
83.26 MAUD+15.44%
72.12 MAUD+10.31%
65.38 MAUD+269.08%
17.72 MAUD-20.75%
22.35 MAUD-6.13%
23.81 MAUD-8.76%
26.10 MAUD-8.29%
28.46 MAUD+163.20%
10.81 MAUD-28.45%
15.11 MAUD+100.01%
7.56 MAUD-13.34%
8.72 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polynovo Stock analysis

What does Polynovo do? Polynovo Ltd is an Australian BioTech company that specializes in the development and manufacturing of medical implants. The company was founded in 1986 under the name Regeneus Ltd and is headquartered in Melbourne. Polynovo's history began with the development of products for the veterinary field. In 2000, the company received approval for the sale of its first human products, which were used for wound treatment. In 2014, the company was renamed Polynovo to emphasize its focus on biological implants for human tissue. Polynovo utilizes a revolutionary technology called NovoSorb, which allows for the production of biodegradable polymer films in various shapes and sizes. These are then used as implants in the human body and naturally degrade within a predetermined timeframe. Polynovo is divided into various divisions, including wound care, plastic surgery, and orthopedics. In wound care, the company offers products that aim to prevent infections and promote natural healing processes. The plastic surgery division provides implants for breast reconstruction and fat transplantation. In orthopedics, Polynovo manufactures implants for joints, bones, and tendons. An example of a Polynovo product is NovoSorb BTM (Biodegradable Temporary Matrix), which is used in burns and other skin defects. The matrix stimulates healing and the formation of new tissue, restoring a normal appearance to the patient. Polynovo's business model is based on long-term relationships with hospitals, medical professionals, and government agencies. The company heavily invests in research and development to continuously improve and expand its technology and product range. Through partnerships with other companies and academic institutions, Polynovo is working towards global distribution of its products. Overall, Polynovo has received various awards over the years, including an innovation award from the Australian Trade Commission, and has been recognized multiple times as one of Australia's fastest-growing companies. In conclusion, Polynovo is an innovative and successful company specializing in the development and manufacturing of biological implants. Thanks to its NovoSorb technology, the company can offer products that help accelerate the healing process and facilitate faster patient recovery. Polynovo is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Polynovo's Equity

Polynovo's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Polynovo's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Polynovo's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Polynovo's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Polynovo’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Polynovo stock

The Equity of Polynovo is 90.70 M AUD in 2026.

The Equity of Polynovo changed from 83.26 M AUD to 90.70 M AUD, representing a 8.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Polynovo since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Polynovo historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Polynovo

All Key Metrics — Polynovo